Generate Biomedicines
Generate Biomedicines is a clinical-stage generative biology company that uses machine learning to design novel protein therapeutics. Founded in 2018 inside Flagship Pioneering's innovation foundry by Avak Kahvejian, Geoffrey von Maltzahn, Molly Gibson, and Gevorg Grigoryan, the company emerged from stealth in September 2020. Its platform learns the fundamental sequence-to-function principles of proteins, enabling it to generate antibodies, enzymes, peptides and other modalities computationally across thousands of programs. Generate trades on Nasdaq under ticker GENB following its February 2026 IPO and has partnerships with Amgen and Novartis.
Public Company
Generate Biomedicines is publicly traded
IPO'd on February 26, 2026
This company is no longer available on our private secondary market. Shares can be traded publicly under GENB.
Overview
Company data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Founded
2018
Employees
250–350
Total Funding
$708M
5 rounds
Funding
Total raised $708M across 5 rounds
Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Last updated 06-25-2026
Latest Round
Type
Strategic (Samsung)
Date
December 18, 2024
Amount
Not disclosed
Valuation
—
Lead Investors
| Date | Round | Amount Raised | Valuation | Lead Investors |
|---|---|---|---|---|
| December 18, 2024 | Strategic (Samsung) | Not disclosed | — | Samsung Life Science Fund |
| September 24, 2024 | Strategic (Novartis equity) | $15M | — | Novartis |
| September 7, 2023 | Series C | $273M | — | Not disclosed |
Prominent Investors
Leadership
Michael Nally
Chief Executive Officer
Geoffrey von Maltzahn
Co-Founder
Gevorg Grigoryan
Co-Founder & Chief Technology Officer
Molly Gibson
Co-Founder
Avak Kahvejian
Co-Founder
Jason Silvers
President & Chief Financial Officer
Competitors
Competitor list is illustrative and may be incomplete, stale, or erroneous.
Isomorphic Labs
Alphabet/DeepMind spinout applying AlphaFold-derived AI models to drug discovery across modalities.
Recursion Pharmaceuticals
Publicly traded AI-driven drug discovery platform (NASDAQ: RXRX) combining phenomics and ML; merged with Exscientia.
Insitro
ML-driven drug discovery company integrating cellular, molecular and clinical data to design novel therapeutics.
Xaira Therapeutics
ARCH/Foresite-backed generative AI biotech using protein design models (RFdiffusion lineage) to develop novel biologics.
Absci
Publicly traded (NASDAQ: ABSI) generative AI antibody discovery platform combining wet-lab and ML for de novo biologics.
EvolutionaryScale
Protein language model company (ESM3) spun out of Meta AI, applying generative models to biology and therapeutics.
Generate Biomedicines Investment FAQ
Generate Biomedicines FAQ
Yes, Generate Biomedicines is publicly traded under the ticker symbol GENB on the Nasdaq Global Select Market. The company went public in February 26, 2026.
Generate Biomedicines trades under the ticker symbol GENB on the Nasdaq Global Select Market. It began trading in February 26, 2026.
Generate Biomedicines (GENB on the Nasdaq Global Select Market) shares can be purchased through any standard brokerage account — including Fidelity, Charles Schwab, TD Ameritrade, and online platforms like Robinhood or E*TRADE. Search for the ticker GENB to place an order.
Generate Biomedicines went public in February 26, 2026 via ipo. Generate Biomedicines completed its IPO on the Nasdaq Global Select Market in February 2026, pricing 25,000,000 shares at $16.00 per share on February 26, 2026 for gross proceeds of $400M. Shares began trading February 27, 2026 under ticker GENB. The IPO was the largest biotech IPO of 2026 to that point, though it priced at the midpoint of the $15-$17 range and opened below the IPO price on debut. The offering reflected a roughly $2.0-$2.2B valuation, above the company's last private Series C valuation of $1.52B.
Generate Biomedicines raised $708M across 5 disclosed funding rounds prior to its public listing.
Generate Biomedicines was co-founded by Geoffrey von Maltzahn, Gevorg Grigoryan, Molly Gibson, and 1 others in 2018.
Generate Biomedicines is headquartered in Somerville, MA.
Access live market data
Sign UpData collected with AI, which can make mistakes. Please double-check this information.